Clinical Trial Update: Open Label Extension Study to Protocol C2/13/DR-6MP-02 [Phase 2]

View source ↗

Summary

A Phase 2 open-label extension study (Protocol C2/13/DR-6MP-02) for Crohn's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Snippet

Sponsor: Teva GTC | Conditions: Crohn's Disease | Phase 2 | Status: WITHDRAWN